Medicare and Medicaid together cover over 150 million Americans — including the elderly, disabled, and low-income populations who often rely most heavily on prescription drugs. Understanding how the 2026 Section 232 pharmaceutical tariff interacts with these programs requires digging into some program-specific mechanics that differ from commercial insurance.
Medicare Part D: The Basics
Medicare Part D is the prescription drug benefit for Medicare enrollees. It is provided through private insurance plans (PDPs) contracted with Medicare. Part D has several distinct cost phases:
- Deductible phase — You pay full drug costs until the deductible is met (up to $590 in 2026)
- Initial coverage phase — You pay copays or coinsurance, insurer pays the rest
- Catastrophic phase — After $2,000 in out-of-pocket costs (2026 cap under IRA), you pay nothing
How the Tariff Affects Part D
The tariff does not directly change Medicare drug coverage rules — but it affects the underlying drug prices that feed into the Part D system.
Short-term impact on beneficiaries: Part D plans negotiate drug prices through pharmacy benefit managers (PBMs). These negotiated prices are what determine your copay in the initial coverage phase. If manufacturers raise list prices in response to tariff costs, PBM-negotiated prices typically adjust at contract renewal — which happens annually.
The $2,000 out-of-pocket cap (IRA 2025): The Inflation Reduction Act established a $2,000 annual out-of-pocket cap for Part D beneficiaries starting in 2025. This means that even if tariff-driven cost increases push drug prices up significantly, no Medicare beneficiary pays more than $2,000/year in drug costs out of pocket. This is a substantial protection for Part D enrollees.
Premium impact: While individual beneficiaries are capped at $2,000 OOP, the overall cost to Part D plans rises as drug costs rise. This eventually feeds into plan premium increases at the annual enrollment period. Beneficiaries should expect Medicare Part D premiums to reflect drug cost trends — including tariff impacts — in the 2027–2028 enrollment cycles.
Low-Income Subsidy (LIS / Extra Help)
Medicare beneficiaries who qualify for the Low-Income Subsidy (also called Extra Help) pay dramatically reduced premiums, deductibles, and copays. LIS recipients are among the best-protected Medicare patients from tariff impact:
- Copays capped at $4.50 for generics and $11.20 for brand-name drugs (2026 benchmark)
- No deductible
- The $2,000 OOP cap applies, but LIS recipients rarely reach it
For LIS patients, the tariff's direct impact is minimal. Generics remain cheap, and the copay caps contain exposure on brand-name drugs.
Medicaid: Manufacturer Rebates as a Buffer
Medicaid drug pricing is governed by a federal rebate system. Manufacturers must pay rebates to state Medicaid programs for covered outpatient drugs — the rebate is a percentage of the Average Manufacturer Price (AMP). This system creates a natural buffer:
If a tariff causes a manufacturer to raise their list price (and thus AMP), the required Medicaid rebate also increases proportionally. This partially offsets the cost increase for the Medicaid program — and for the patient, Medicaid copays are usually fixed at very low amounts ($1–$4 depending on state and drug tier).
Practical reality for Medicaid patients: Your copay for a prescription drug through Medicaid will almost certainly not change because of the tariff. Medicaid copay structures are set by state regulation and change slowly. The tariff costs are absorbed at the program level, not passed to enrollees.
Drugs Covered Under Medicare Part B (Medical Benefit)
Many specialty drugs — biologics, infusions, chemotherapy, and drugs administered in a clinical setting — are covered under Medicare Part B (medical benefit) rather than Part D. Part B drug reimbursement is typically set at 106% of the Average Sales Price (ASP).
For Part B drugs from companies with MFN deals (Merck's Keytruda, BMS's Opdivo, Genentech's Avastin) — 0% tariff means their ASP-based pricing is unaffected. For Part B drugs from non-Annex III companies, tariff-driven price increases would flow into ASP over time — typically with a 2-quarter lag in the ASP reporting cycle.
The Bottom Line for Medicare/Medicaid Patients
Medicaid patients: Minimal direct impact. Fixed low copays, manufacturer rebate system absorbs much of the cost increase, generics (90% of prescriptions) fully exempt.
Medicare Part D patients with LIS: Well protected. Low fixed copays and the $2,000 OOP cap together create strong insulation.
Standard Medicare Part D patients: Protected from extreme out-of-pocket costs by the $2,000 annual cap. However, tariff-driven price increases could cause patients to reach the OOP cap earlier in the year, and plan premiums may increase in future enrollment years.
Check your specific drug's tariff status with the RxTariff drug search tool and consult your State Health Insurance Assistance Program (SHIP) counselor for personalized Medicare drug coverage advice.